New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Editas Medicine, Inc. (EDIT) vs SAB Biotherapeutics, Inc. (SABS)
- Editas Medicine, Inc. EDIT 1.64 −4.09%
- SAB Biotherapeutics, Inc. SABS 2.81 −3.44%
Editas Medicine, Inc. and SAB Biotherapeutics, Inc. are both Biotechnology companies. Editas Medicine, Inc. and SAB Biotherapeutics, Inc. are of similar size ($263.9M and $262.2M). Editas Medicine, Inc. grew revenue faster over the last twelve months: 7.42% against −56.7%. Editas Medicine, Inc. has the higher net margin (−145.0% vs −1,450.3%) and the higher return on invested capital (0.00% vs −48.4%). Across the 16 metrics below, Editas Medicine, Inc. leads on 10 and SAB Biotherapeutics, Inc. on 6.
Valuation
Profitability
| Metric | EDIT | SABS | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 70.18% |
| Operating margin | (151.71%) | (1,647.03%) | 0.00% |
| Net margin | (144.95%) | (1,450.32%) | 0.00% |
| Free cash flow margin | (221.15%) | (1,344.29%) | 0.00% |
| Return on equity | (147.44%) | (47.62%) | (51.58%) |
| Return on assets | (34.30%) | (42.73%) | (45.91%) |
| Return on invested capital | 0.00% | (48.38%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack